Roche to invest CAD$190m in Canadian research site

Published: 23-Aug-2011
Research & Development Finance Pharmaceutical

It will include operations for all stages of global clinical trial research and create opportunities for r&d partnerships

Roche Canada is to invest more than CAD$190m (£117m) over the next five years in a new global development site in Ontario, Canada, creating around 200 skilled jobs.

The facility in Mississauga will be set up with additional funding of CAD$7.79m from Ontario’s Ministry of Economic Development and Trade. It will include operations for all stages of global clinical trial research and create opportunities for r&d partnerships with Ontario’s research and teaching hospitals, universities and other research institutions.

The Ontario government has also recently made similar investments in projects by Teva, GlaxoSmithKline and Pfizer.

Roche Canada said it chose Ontario because it offers the environment to support drug discovery and development, including an educated and capable workforce, and a business environment supported by a government that places a high strategic priority on life sciences.

‘As a leader in research and development, and biotechnology, we are extremely pleased to bring global pharmaceutical development opportunities to Ontario,’ said Ronnie Miller, president and ceo of Roche Canada.

‘We have built a respected clinical expertise within the Roche global network, and this new capability will firmly establish Roche Canada as a global hub for life sciences and biopharmaceuticals.’

Over the next five years, jobs in areas such as global trial and data management will be offered. The first positions have already been filled.

Roche says renovations to house the global site will begin during the summer, and several more positions will be filled by autumn. With this expansion, Roche will have more than 650 employees in Ontario.

Roche Canada was founded in 1931. The company employs approximately 900 people across the country, with its pharmaceuticals head office located in Mississauga and diagnostics division in Laval, Quebec.

See more

You may also like

Research & Development

Roche launches global Phase III Elevidys trial to support EU approval for Duchenne gene therapy

Read more
Roche has initiated a new Phase III study of Elevidys, aiming to generate placebo-controlled data for European Medicines Agency resubmission and expand access to the Duchenne muscular dystrophy gene therapy

Trending Articles

  1. Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Britain's biotech potential (part I): world-class science, second-class support? The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
  4. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  5. Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Research & Development

Roche launches global Phase III Elevidys trial to support EU approval for Duchenne gene therapy

Roche has initiated a new Phase III study of Elevidys, aiming to generate placebo-controlled data for European Medicines Agency resubmission and expand access to the Duchenne muscular dystrophy gene therapy
Research & Development

Roche to put $50bn into US manufacturing and R&D footprint

The company will build new gene therapy, weight loss medication and continuous glucose monitoring manufacturing facilities situated across the US, as well as dedicated R&D centres
Manufacturing

Roche expands GLP-1 cardiometabolic portfolio with Zealand Pharma collaboration

Together, the companies will co-develop and commercialise a combination of Zealand Pharma's amylin analog, petrelintide, and Roche's lead incretin GLP-1 receptor agonist, CT-388
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Roche's breast cancer combination therapy Itovebi bags FDA approval

Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients
Finance

Lonza completes acquisition of large-scale biologics site in Vacaville (US) from Roche

Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Subscribe now